Tuesday 23rd April 2024
RAIRDA Survey
Have your say on the way your services are working for your Rare Autoimmune Rheumatic Disease (RAIRD)
Dr. Elizabeth Renzoni has been working as a consultant respiratory physician at Royal Brompton Hospital in the ILD Unit and an honorary senior lecturer at Imperial College London since 2006. We spoke to her about her career in research.
Here at Scleroderma and Raynaud's UK, we invest in research to save lives. The more research we can conduct into both scleroderma and Raynaud's, the closer we get to having better treatments and eventually a cure. Thanks to your support, SRUK is able to work with a number of dedicated, inspiring scientists who all endeavour to further understanding of the two conditions. We do this to improve the quality of people's lives, and ultimately to save lives. Each research scientist has experienced varying journeys to accomplish their many impressive achievements. Here is a little insight into the lives of some of the researchers we fund, what keeps them in the laboratory and the future of research.
at the ILD Unit at Royal Brompton Hospital. She went on to complete a PhD in gene expression analysis in pulmonary fibrosis with Imperial College, London. Since 2006, Elizabeth has been working as a consultant respiratory physician at Royal Brompton Hospital in the ILD Unit and an honorary senior lecturer at Imperial College London. As the oesophagus is so often involved in scleroderma, SRUK have most recently funded a project led by Elizabeth which is assessing the role of chronic microaspiration of small droplets from the stomach into the lungs) in pulmonary fibrosis.
although it is important to note that patients with scleroderma-associated lung fibrosis tend to do much better than those with IPF. Two drugs have recently been found to be effective in the treatment of IPF, as they can slow down the progression of lung fibrosis, and so these same drugs are also being trialled in scleroderma-associated lung fibrosis, with the first results expected over the next year. I believe in the next five years, there will continue to be interconnections between discoveries and treatment options from the field of IPF to scleroderma-associated lung disease.
.
Tuesday 23rd April 2024
Have your say on the way your services are working for your Rare Autoimmune Rheumatic Disease (RAIRD)
Tuesday 19th March 2024
The Scleroderma and Raynaud’s UK sponsored 'Science in Medicine School Teams Prize 2024' contest is now open for entries. The contest aims to engage sixth form school students with science in medicine, and challenges students to prepare an ePoster with a novel vision on how to promote the health and well-being of individuals with Scleroderma and/or Raynaud’s. If you're interested in entering, or know someone in sixth form who might be, read on to find out more!
Wednesday 28th February 2024
As high bills continue to threaten the health of those living with the debilitating condition; SRUK is appealing to energy companies to provide financial assistance to them.